Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer
Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer
Ophthalmology drug development leader joins to advance OCT-980 and further develop clinical capabilities supporting Octant’s pipeline
Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced the appointment of Eddy Anglade, M.D., as its first Chief Medical Officer. Dr. Anglade will lead Octant’s clinical development strategy, including advancing its lead program, OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP).
“OCT-980 is the first molecule from our platform to reach patients, and more are coming behind it,” said Sri Kosuri, co-founder and Chief Executive Officer of Octant. “Eddy has led development from first-in-human studies through late-stage programs, and he is the right person to lead these programs through the clinic and get them to the patients who need them.”
Dr. Anglade brings more than 20 years of experience leading drug development across ophthalmology, rare disease and regenerative medicine. He most recently served as Chief Executive Officer of Tenpoint Therapeutics. Previously, he was Vice President and Clinical Lead, Retina at Janssen Research & Development, where he led strategy for its development-stage retinal programs. At Astellas Pharma, he served as Global Therapeutic Area Head, Ophthalmology, having joined through its acquisition of Ocata Therapeutics, where he was Chief Medical Officer. He also co-founded Lux Biosciences and served as its Chief Medical Officer. Dr. Anglade received his M.D. from Yale University School of Medicine and completed his ophthalmology residency at Massachusetts Eye and Ear/Harvard Medical School, with additional training at the National Eye Institute.
"Patients with RHO-adRP have no approved therapies. OCT-980 addresses the root cause of their disease," said Dr. Anglade. "I am thrilled to join Octant and look forward to leading the clinical development of OCT-980 as we work to change that."
About Octant
Octant is a clinical-stage drug discovery company developing small-molecule correctors for protein misfolding diseases. Octant's platform, The Navigator, combines high-throughput synthetic biology, scaled chemistry, and AI/ML to discover and develop therapeutics against complex cellular mechanisms in human cells. The company's pipeline is led by OCT-980, an investigational oral small molecule currently being evaluated in a Phase 1b/2 clinical trial for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). Octant's pipeline also includes programs across other rare diseases and oncology. For more information, visit www.octant.bio.
Tarek Saoud
(510) 224-4321
press@octant.bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117150399/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?
